Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006390 · ClinicalTrials.gov registry record · Phase 2
Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006390: Completed Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
NCT00006390 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006390, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as alemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy. Combining monoclonal antibody therapy, chemotherapy, radiation therapy, and peripheral stem cell transplantation may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of alemtuzumab plus peripheral stem cell transplantation in treating patients who have chronic lymphocytic leukemia.
Interventions
- DRUG cyclophosphamide
- RADIATION radiation therapy
- BIOLOGICAL alemtuzumab
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07-05 |
| Phase | Phase 2 |
What the finished NCT00006390 record still lists
NCT00006390 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00006390 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006390 about?
NCT00006390 is a clinical study titled "Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia". RATIONALE: Monoclonal antibodies such as alemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy...
What is the current status of trial NCT00006390?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-07-05.
What interventions are being tested in trial NCT00006390?
The interventions under investigation include: cyclophosphamide (DRUG), radiation therapy (RADIATION), alemtuzumab (BIOLOGICAL), peripheral blood stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006390?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI